What we're reading ... February 26, 2010

Article

Fertility

The first woman to give birth to a second baby after ovarian tissue transplant was featured in an Associated Press article I saw in the Washington Post: "Woman 1st giving birth twice with ovary transplant." Before receiving chemotherapy for bone cancer, Stinne Holm Bergholdt of Denmark had a portion of her ovary removed. Doctors transplanted a portion of that ovary after Bergholdt completed therapy a year later. The transplant took and Bergholdt now has two beautiful children. This is very encouraging news for women seeking to preserve fertility during cancer treatment.

Lena Huang

Fitness & Nutrition editorCancer Strategy

An interesting Forbes article "The Mathematics of Cancer," highlights how Larry Norton, a leading breast oncologist at Memorial Sloan-Kettering Cancer Center, and other scientists believe that by stopping cancer from spreading--instead of just multiplying--may lead to better and curative treatments. We touched on a similar topic in Heal with Mutations & Math. Both are worth a look!

Elizabeth Whittington

Managing editor, curetoday.comClinical Trials

This is a three-part series (Target Cancer) done by the New York Times looking at a clinical trial for a melanoma drug. It dives into the various aspects of being involved in a clinical trial--from the doctor and patient perspectives. I think it provided a great visual of the ups and downs of being involved in the clinical trials, the risk that everyone involved has to take, and the moments of despair when there's a failed outcome or the moment of triumph when the outcome is good. Each article is accompanied by a video, and there's a "Q&A on clinical trials" blog that the writer, Amy Harmon, moderates.

Bunmi Ishola

Editorial assistantUpdates

A great resource for those who want to keep up with the latest in cancer findings is to sign up for the National Cancer Institute Bulletin. Every issue has the latest findings from major scientific journals, in-depth articles, special reports, clinical trial information, legislative updates, and federal agency news. The latest bulletin includes research on hypofractionated radiation, kidney cancer, chemotherapy-induced peripheral neuropathy, and more.

Kathy LaTour

Editor-at-Large

Related Videos
For patients with cancer, the ongoing chemotherapy shortage may cause some anxiety as they wonder how they will receive their drugs. However, measuring drugs “down to the minutiae of the milligrams” helped patients receive the drugs they needed, said Alison Tray. Tray is an advanced oncology certified nurse practitioner and current vice president of ambulatory operations at Rutgers Cancer Institute in New Jersey.  If patients are concerned about getting their cancer drugs, Tray noted that having “an open conversation” between patients and providers is key.  “As a provider and a nurse myself, having that conversation, that reassurance and sharing the information is a two-way conversation,” she said. “So just knowing that we're taking care of you, we're going to make sure that you receive the care that you need is the key takeaway.” In June 2023, many patients were unable to receive certain chemotherapy drugs, such as carboplatin and cisplatin because of an ongoing shortage. By October 2023, experts saw an improvement, although the “ongoing crisis” remained.  READ MORE: Patients With Lung Cancer Face Unmet Needs During Drug Shortages “We’re really proud of the work that we could do and achieve that through a critical drug shortage,” Tray said. “None of our patients missed a dose of chemotherapy and we were able to provide that for them.” Tray sat down with CURE® during the 49th Annual Oncology Nursing Society Annual Congress to discuss the ongoing chemo shortage and how patients and care teams approached these challenges. Transcript: Particularly at Hartford HealthCare, when we established this infrastructure, our goal was to make sure that every patient would get the treatment that they need and require, utilizing the data that we have from ASCO guidelines to ensure that we're getting the optimal high-quality standard of care in a timely fashion that we didn't have to delay therapies. So, we were able to do that by going down to the minutiae of the milligrams on hand, particularly when we had a lot of critical drug shortages. So it was really creating that process to really ensure that every patient would get the treatment that they needed. For more news on cancer updates, research and education, don’t forget to subscribe to CURE®’s newsletters here.
Yuliya P.L Linhares, MD, an expert on CLL
Yuliya P.L Linhares, MD, and Josie Montegaard, MSN, AGPCNP-BC, experts on CLL
Image of a man with a beard.
Image of a man with gray facial hair and a navy blue suit with a light orange tie.
Image of a woman with black hair.
Related Content